[Form 4] Astera Labs, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Astera Labs (ALAB) – Form 4 insider activity filed 07/07/2025

Director Manuel Alba disclosed the sale of 93,991 common shares on 02-03 July 2025. The disposals were executed through Casa Alameda 2007 LLC (13,991 sh) and the Alba Trust (80,000 sh) under a pre-arranged Rule 10b5-1 trading plan. Weighted-average sale prices ranged from $88.19 to $93.14 across 20 separate trades. No derivative securities were involved.

Following the transactions, Alba still beneficially owns about 2.31 million shares (1.89 m via Alba Trust, 418.9 k via Casa Alameda, 5 k via spouse, 2.4 k directly), indicating he retained roughly 96 % of his prior position.

The filing signals modest insider selling—around 4 % of his holdings—but the continuing sizeable stake and use of a 10b5-1 plan temper potential negative interpretation.

Positive

• Sales were executed under a pre-existing Rule 10b5-1 plan, limiting concerns over potential misuse of non-public information.
• Director retains a significant 2.3 million-share position, maintaining alignment with long-term shareholder interests.

Negative

• Director disposed of 93,991 shares (~4 % of his holdings), an insider-selling action that can be viewed as a modestly bearish signal.
• No insider purchases were reported, so net insider activity is negative over the disclosed period.

Insights

Securities Analyst

TL;DR: Director sells ~94k ALAB shares (≈4 % stake) via 10b5-1; mildly bearish but ownership remains substantial.

Alba’s sale represents a small fraction of his total holdings, yet any insider disposition can raise eyebrows, particularly shortly after Astera Labs’ March IPO. The weighted-average prices clustered just below $93 suggest opportunistic profit-taking during recent strength. Because the trades were executed under a pre-scheduled Rule 10b5-1 plan, the informational value is reduced and regulatory risk minimal. With 2.31 million shares still held, alignment with shareholders largely persists. Overall, the event is incrementally negative for sentiment but unlikely to materially impact valuation or liquidity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALBA MANUEL

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		S(1)		4,278	D	$88.7099(2)	428,576	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/02/2025		S(1)		2,819	D	$89.5773(4)	425,757	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/02/2025		S(1)		2,448	D	$90.6189(5)	423,309	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/02/2025		S(1)		1,654	D	$91.6238(6)	421,655	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/02/2025		S(1)		801	D	$92.3655(7)	420,854	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/02/2025		S(1)		18,179	D	$88.7099(2)	1,949,578	I	By Alba Trust(8)
Common Stock	07/02/2025		S(1)		11,980	D	$89.5772(4)	1,937,598	I	By Alba Trust(8)
Common Stock	07/02/2025		S(1)		10,404	D	$90.6188(5)	1,927,194	I	By Alba Trust(8)
Common Stock	07/02/2025		S(1)		7,030	D	$91.6236(6)	1,920,164	I	By Alba Trust(8)
Common Stock	07/02/2025		S(1)		3,407	D	$92.3657(7)	1,916,757	I	By Alba Trust(8)
Common Stock	07/03/2025		S(1)		195	D	$89.7354(9)	420,659	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/03/2025		S(1)		837	D	$90.585(10)	419,822	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/03/2025		S(1)		543	D	$91.4933(11)	419,279	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/03/2025		S(1)		413	D	$92.3775(12)	418,866	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/03/2025		S(1)		3	D	$93.14	418,863	I	By Casa Alameda 2007, LLC(3)
Common Stock	07/03/2025		S(1)		2,835	D	$89.7373(9)	1,913,922	I	By Alba Trust(8)
Common Stock	07/03/2025		S(1)		12,185	D	$90.5849(10)	1,901,737	I	By Alba Trust(8)
Common Stock	07/03/2025		S(1)		7,914	D	$91.493(11)	1,893,823	I	By Alba Trust(8)
Common Stock	07/03/2025		S(1)		6,018	D	$92.3778(12)	1,887,805	I	By Alba Trust(8)
Common Stock	07/03/2025		S(1)		48	D	$93.14	1,887,757	I	By Alba Trust(8)
Common Stock								5,000	I	By spouse
Common Stock								2,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.1900 to $89.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. These shares are owned directly by Casa Alameda 2007, LLC, of which the Reporting Person is a manager. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.1900 to $90.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.1900 to $91.1800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.1900 to $92.1850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.1900 to $92.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. These shares are owned directly by Manuel Alba-Marquez in trust for Alba 2003 Living Trust (the "Alba Trust"), of which the Reporting Person and his spouse are co-trustees. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.0500 to $90.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.0500 to $91.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.0500 to $92.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.0500 to $92.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Astera Labs (ALAB) shares did Director Manuel Alba sell?

Alba sold 93,991 common shares over two trading days.

When were the ALAB insider sales executed?

The transactions occurred on July 2 and July 3, 2025.

What price range did the ALAB shares sell for?

Weighted-average prices ranged between $88.19 and $93.14 per share.

How many ALAB shares does Manuel Alba still own after the sales?

He retains roughly 2.31 million shares through various entities and direct holdings.

Were the insider sales conducted under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the trades were made automatically pursuant to a 10b5-1 plan adopted on May 31, 2024.